Anti-cancer compounds and methods related thereto

Field of the Invention

[0002] The present invention relates generally to the field of cancer treatments, as well as to the field of peptide and non-peptide pharmaceutical compounds.

BACKGROUND OF THE INVENTION

[0003] Many lung and prostate cancers, of which small cell lung cancer (SCLC) is a prime example, have a neuroendocrine phenotype, and their growth is stimulated by neuropeptides. Antagonists of several peptides (e.g. bradykinin, substance P. bombesin) have been used in experimental treatment of models of SCLC in animals. Among the most potent of the peptides examined thus far, crosslinked dimers of certain bradykinin antagonist peptides have been efficacious both in vitro and in vivo against strains of SCLC and other tumors (Chan et al., Immunopharmacology 33: 201-204, 1996; Stewart et al., Can. J. Physiol. Pharmacol. 75: 719-724, 1997; Stewart et al., U.S. Pat. No. 5,849,863, issued Dec. 15, 1998). Prostate cancers show a similar neuroendocrine phenotype and are susceptible to neuropeptide antagonists.

SUMMARY OF THE INVENTION

[0004] The present invention provides anti-cancer agents (ACA) comprised of a range of novel amino acid derivatives and small peptides having the ability to inhibit growth of SCLC and certain other tumor cell lines (such as non-small cell lung cancer (NSCLC) and prostate cancer) in standard in vitro tests, as well as certain monomeric peptides that show inhibition of tumor growth in vivo. Certain of the peptides have a general structural relationship to carboxy-terminal fragments of bradykinin antagonists, but the non-peptides show no such general relationship.

[0005] Monomers, dimers, trimers, tetramers, pentamers and cyclized analogs of the novel molecules are described. The new compounds are tested for bradykinin antagonist activity in standard assays, but there is no apparent relationship between bradykinin antagonist activity and cytolytic potency. All of the molecules described possess both hydrophobic (usually aromatic) and basic groups in their structures. Without being held to one particular theory, it appears that the compounds function by stimulation of cell death (apoptosis) in the tumor cells.

[0006] The present invention also provides compounds and methods for inhibiting cancer by administering to a subject afflicted with cancer (ie. of the lung or prostate) a therapeutically effective amount of one or more of the compounds herein described.

[0007] In general, the anti-cancer compounds are described by the formula:

[ACA]n−X [Formula I]

[0008] wherein X is a linker having 2-5 functional groups or is absent, n=1-5, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI. Other compounds described herein are defined by the Formula VII. The specifics regarding structure are enumerated in the Detailed Description, Examples and Claims. Certain physical charateristics are enumerated in the Examples as well as the Detailed Description, Examples and Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009]
FIG. 1 shows inhibition of growth in vivo of SCLC strain SHP-77 by B10054.

[0010]
FIG. 2 shows inhibition of growth in vivo of NSCLC strain A-549 by M620.

[0011]
FIG. 3 shows inhibition of growth in vivo of SCLC strain SHP-77 by B9430.

[0012]
FIG. 4 shows inhibition of growth in vivo of SCLC strain SHP-77 by B1023

[0013]
FIG. 5 shows inhibition of growth in vivo of SCLC strain SHP-77 by M570, both as the trifluoroacetate salt and as the hydrochloride salt.

[0014]
FIG. 6 shows inhibition of growth in vivo of SCLC strain SHP-77 by M822.

[0015]
FIG. 7 shows inhibition of growth in vivo of SCLC strain SHP-77 by M638.

DETAILED DESCRIPTION OF THE INVENTION

[0016] The present invention provides a range of monomeric, dimeric, trimeric, tetrameric, pentameric and cyclic small peptides and peptide mimics that are effective as anti-cancer agents.

[0017] In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n−X [Formula I]

[0018] wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

[0019] X can be any linking group which does not interfere with the inhibitory activity of the monomer-linker or oligomerized product using bis-imido-esters, bis-maleimidoalkanes such as bis-maleimidohexane, dicarboxylic acids, tricarboxylic acids, tetracarboxylic acids and multi carboxylic acids. Alkane groups may be substituted with alkyl, amino, carboxyl, halogen, hydroxy, mercapto or methoxy groups. Aminoalkyl, aromatic or cycloalkyl polycarboxylic acids, heterocyclic polycarboxylic acids, carboxylic anhydrides and polyoxyethylene linkers may also be used. For C-terminal crosslinking, X may be any diamino or polyamino alkane, cycloalkane, aromatic, heterocyclic diamine, polyamine or other substituted chelating agent (for example: diethylenetriaminepentaacetic dianhydride, ethylenediaminetetraacetic dianhydride, etc.). Polyamino-polycarboxylic acids may also be used to make heteromers (such as ethylenediamine-N,N′-diacetic acid, etc.).

[0020] The linkage may be at the N-terminal or the C-terminal or at any position of the ACA sequence through side-chain functional groups. The linker may have any chain length.

[0021] For dimers, there is a correspondence between linker length and cytotoxicity. Alkyl chains of 8 carbons or more are preferred, with those of 8 to 18 carbons being most preferred. Examples of preferred dimer linkers for the α-amino at the N-terminal or for a basic side-chain group at any position of ACA include ADA, BTAC, DDD, DDS, DTP, EGS, EOPC, HDD, HFG, PFS, SBEC, SUB, SUIM and TDIM. For dimerization through the C-terminal carboxyl or any side-chain carboxyl in ACA, the preferred linkers include DDA, DEA, EDA, EDP and HAD. Any di-functional molecule can be used.

[0022] For trimers, linkers for basic groups include BTAC, BTC, CHTC, CTAC and TREN-(Suc)3; for carboxyl groups, TREN. Any tri-functional molecule can be used.

[0023] For tetramers, linkers can be BAPTA, CPTA, EDTA, EGTA, ETTA, or any tetra-functional molecule.

[0024] For pentamers, the linker can be DTPA or any pentameric functional molecule. Compounds formed by ACA and a linker X may be homo or hetero multimers.

[0025] [Formula II] comprises:

R-A−1-B0-C1-D2-E3-F4-G5-H6-I7-J8K9

[0026] wherein R, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent, and wherein K is Arg or an Arg derivative:

1ABCDEFGHIJKR−10123456789AbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentororororOrororororororor3,3DPDmKApcApCMePHypAvaAddArg2Nal2NalArgAaaLysArgArgNigProBAlaAudGlyDCpG2Nal-Arg(H)AcLys(εFDArgDmKNMFDprCpGPacDF5FNH2Arg-lu)CH2OHAcaNiKDLysNiKProEacDDMFPacDIgl3,4F2FArg-BApgPzODmKNiOGlyDMFSerDPFF3PalArg(NO2)CcaDniKPaFEacThrDPheAc6cArg-OMeCinDpaFPzOIglDTicAicDArgDcaDPZKLysGlyAnaDArg-NH2DcgDPzOPacmABzApbDArg(NO2)DhqLysPhepABzApbDmacNiKThiPacAtpcDpaPaFPaF(DcBipg)F5bzPzOpAmbCmpF5cDArg-Arg-CpG(NO2)(NO2)F5paDhPheGunDpr(Fbz)HxaDpr(Paa)McaFSFMcgF5F-NH2MotiHphePccIcaPpaIglPyaIgl-NH2SaaIleuSteLys(CH3)3TfmcLys(F5bz)MapaMBCMFFNc6GNc7GNMFOBSOBTOBYOC2YOicOic-NH2PABzPacPaF(F5c)PaF(Fbz)PaF(Mcg)PaF(Ppa)PaF(Sin)pAmbpAPaPCFPdFPFFPFF-NH2PhePNFThiTicTrpTrxTyr

[0027] [Formula III] comprises:

R-A1-B2-C3-D4-E5-F6

[0028] wherein R, A, B, C, D, E, and F are selected from the following or may be absent, and wherein F is not Arg or an Arg derivative:

2ABCDEFR123456Absent orAbsent orAbsent orAbsent orAbsent orAbsent orAbsent or2,2DpDArgArgAdd2NaliNal2Nal3,3DpDArg(NO2)Aud3Pal2Nal3PalAaaAvaArg2NapABzaAcRaeArg(Tos)3PalABzaAcaLysAtopApaAmaBocPacD2NaIArgAmpyChcDArgArg-NH2AmpzCinDArg(Tos)AspApaCtimDFSFAtcApiDcaDIgIAtopAptpDcgDPFFBipAqdDhqEacBtAAquDmacF5FCys(Meb)Arg(H)DnsGlyCys(SO3H)Arg-CH2OHDpaHisD2Na1Arg-NH2F5cIg1DArgArg-OMeF5pamABzDArg-NH2AspF5poOC2YF5FAsp(Aqu)GbcPacGluAtcpGunPFFGlyAtmpHxaIglAtmpOMcgInpAtpmMseIqaCyhPyamABzDmabSebMC2YDmmSinN-Dmb-DmpTyr(Bz)-OMeSulOC2YDpeaTfmcOCIYDpmaThaOicDpr(Dcg-2-Nap)pABzEcapPaF(Mes)F5F-NH2PITGaPTicmA2BztLeumA2Bz(Dcg)TrpmA2Bz(Gun)TrymABzTry(Bzl)MappTyrMatpArg(NO2)MatpOpABzPaFPaF(Dcg)PaF(Mcg)PaF-NH2PFF-NH2PgFPzOSudThmThmnTpacTpacTyr(Bz)OMe

[0029] [Formula IV] comprises:

A0-B1-C2-D3-E4-F5-G6-H7-I8-J9-K10-L11

[0030] wherein A, B, C, D, B, F, G, H, I, J, K and L are selected from the following or may be absent:

3ABCDEFGHIJKL01234567891011AbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentororororororororororororDArgArgProLysProDTrpGlnDTrpPheDTrpLeu(r)Leu-DArgDNMFNH2Leu

[0031] [Formula V] comprises:

X-c[A−1-B0-C1-D2-E3-F4-G5-H6-I7-J8-K9]

[0032] wherein X, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent:

4ABCDEFGHIJKX−10123456789AbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentAbsentororororororororororororα-AcaAvaDArgArgProHypGlyAddDArgDDabDTrpArg3,3DpBAlaDNikNiKAddSerDDprF5FLeuDmKDPaFPzOAvaThrDF5FLysNiKGltDPZKBAlaDIglNc7GPaFLysDPzODNMFDLysOic3PalSucEacDOmPaFIglDPaFPFFThiNigPhePacPhe

[0033] [Formula V] also comprises:

X-c[A−1-B0-C1-D2-E3-F4-G5-H6I7-J8]-K9

[0034] [Formula V] also comprises:

X-c[A−1-B0-C1-D2-E3-F4-G5-H6-I7]-J8-K9

[0035] wherein the cyclization is via a side chain functional group other than the C-terminal residue and the residues are as described in the immediately preceding table.

[0036] [Formula VI] comprises the following cyclic peptides:

5B9458-2

B9462

[0037] ACA can also be those compounds in Table 4.

[0038] [Formula VII] comprises:

[ACA]1-Eac-Eac-[ACA]2

[0039] wherein [ACA] is defined by Formula I or the compounds in Table 4.

[0040] The in vivo inhibitory effects of antagonists may be studied using tumor-bearing nude mice. A tumor model employing nude mice orthotopically implanted with human lung cancer cells wherein the ACA is delivered by intratracheal instillation and aerosol inhalation may be used to evaluate the efficacy and feasibility of these antagonists as a means of treating human lung cancers. Control animals without tumor implantation may also be used to study the general side effects or cytotoxicity of the compounds. It is believed that aerosolized delivery or intratracheal instillation of the agents can produce effective dose accumulation in the area of lesion and reduce the overall systemic toxicity of the compounds in the animals more than when the compound is delivered by systemic administration.

[0041] The compounds may be administered topically, or by injection or infusion or as an oral suspension in an appropriate vehicle or as tablets, pills, capsules, caplets or the like, or preferably via intratracheal instillation or aerosol inhalation. The dosage and manner of administration will be defined by the application of the ACA and can be determined by routine methods of clinical testing to find the optimum dose. These doses are expected to be in the range of 0.001 mg/Kg to 100 mg/Kg of active compound.

[0042] The compounds are composed of amino acids which may form salts due to their acidic or basic nature, and any pharmacologically acceptable salt derived from the compounds described in this invention such as hydrochlorides, acetates, phosphates, maleates, citrates, benzoates, salicylates, succinates, ascorbates and the like, including HCl, trifluoroacetic acid (TFA), and HOAc, are considered an extension of this invention. A common tactic in medicinal chemistry is to modify known drug substances which are peptide based to form esters or amides which exhibit greater bioavailability. Prodrugs derived from the compounds disclosed here are therefore considered an obvious extension of this invention. Methods for designing and preparing prodrugs are described in detail in the medicinal chemical literature.

[0043] Structures and biological activities of peptides and peptide mimics related to bradykinin (BKR) are given in Table 1. Structures and biological activities of compounds not related to bradykinin (BKU) are given in Table 2. Structures and biological activities of cyclic peptides are given in Table 3. Structures of previously described known peptides which we have found to be active against cancers in vivo are included in Table 4. Actions of selected compounds on prostate cancer cell lines are given in Table 5. Abbreviations used are as defined in Table 6.

EXAMPLES

[0044] In general, Anti-bradykinin activity was determined by the classical guinea pig ileum assay and on Chinese hamster ovary (CHO) cells expressing cloned human bradykinin B2 receptors. Anti-tumor activity was determined on cultured human cancer cell lines using the standard tetrazolium (MTT) assay. No correlation between anti-bradykinin and cytolytic activity was found among the compounds, indicating that cells are not killed due to inhibition of an essential bradykinin function. Potent compounds were found to stimulate apoptosis in SCLC cells, probably by abnormal activation of the intracellular MEKK pathway.

Example I

Synthesis of Peptides

[0045] Peptides were synthesized using standard solid phase synthesis methods, well known in the art (Stewart and Young, Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, Ill., 1984) and were purified by HPLC and were characterized by amino acid analysis (AAA), thin layer chromatography (TLC) and laser desorption mass spectrometry (LDMS). Peptide amides were synthesized on methylbenzhydrylamine (MBHA) resin, which yields amides directly. Peptide methyl esters (OMe) were synthesized by reaction of peptides with 2,2-dimethoxypropane (Rachele, J. Org. Chem. 28: 2898, 1963). Cyclic peptides were prepared on resin or in solution with PyAOP and HOAt.

Example II

Synthesis of Non-peptides

[0046] Non-peptides were synthesized by standard organic chemistry procedures well known in the art. Compounds were purified by HPLC and were characterized by analytical HPLC, TLC, and LDMS.

Example III

Synthesis of DDD and SUB Dimers

[0047] Synthesis on resin: Neutralized peptide-resin (0.05 mmole) was treated with 0.15 mmole diisopropylethyl amine (DIEA) and 0.026 mmole dodecanedioyl dichloride or suberoyl dichloride in 2.5 mL dichloromethane (DCM). The suspension was mixed for 5 h, washed with DCM and ethanol and dried. The peptide dimer was cleaved from the resin with HF, and the peptide was extracted and purified

[0048] Synthesis in solution: Carboxyl-derivatized amino acids or dipeptides were dissolved in dimethyl formamide (DMF) and treated with 10 equivalents of DIEA and 0.55 equivalent of dodecanedioyl dichloride or suberoyl dichloride overnight. The DMF was evaporated in vacuo and the resulting dimer was purified by HPLC.

Example IV

Synthesis of EGS, DTP, SBEC and SUB Dimers in Solution

[0049] Dimerization in solution proceeded by reacting 1 equivalent of peptide monomer trifluoroacetate, an excess of DIEA and 0.55 equivalent of cross-linking reagent overnight in DMF. The cross-linking agents were purchased from Pierce (EGS dimer, ethylene glycol bis-(succinimidylsuccinate); DTP dimer, dithiobis (succinimidyl propionate); SBEC dimer, bis[(2(succinimidooxycarbonyloxy)ethyl]sulfone; SUB dimer, disuccinimidyl suberate).

Example V

Synthesis of Boc-N-cycloheptylglycine (Nc7G)

[0050] N-Cycloheptylglycine was synthesized by reductive amination of cycloheptanone with glycine methyl ester following the procedure described in Gera et al., Immunopharmacology. 33:174-177 (1996). The crude product was converted to the N-Boc derivative (mp, 89-90° C).

Example VI

Synthesis of TDIM Dimers

[0051] Dimethyl tetradecyldiimidate was synthesized from tetradecanedinitrile by the method of De Abreu et al. (Eur. J. Biochem. 97: 379-387, 1979. One equivalent of peptide TFA salt or other molecule having a free amino group was dissolved in DMF and stirred with 10 equivalents of DIEA and 0.7 equivalent of dimethyl tetradecyldiimidate dihydrochloride overnight at room temperature. DMF was evaporated in vacuo and the dimer was purified. SUIM dimers were prepared similarly, using dimethyl suberimidate.

Example VII

Synthesis of B10238: F5C-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-(F5c-B9430)

[0052] B10238 was made by standard solid phase synthesis procedures, or by the acylation of B9430 with 2,3,4,5,6-pentafluorocinnamic acid in DMF, using BOP coupling in presence of excess DIEA. The product was purified by HPLC.

EXAMPLE VIII

Synthesis of M822: DDD-(DArg-F5F-Arg)2

[0053] Following standard solid phase synthesis procedures, Boc-Arg(Tos) Merrifield synthesis resin was coupled with Boc-F5F, followed by coupling with Boc-DArg(Tos), using HATU as coupling agent. The peptide-resin was deprotected with TFA-DCM and neutralized with TEA. The peptide-resin was then treated with 0.55 equivalent of dodecanedioyl dichloride and 5 equivalents of DIEA in DCM overnight at room temperature. After washing and drying, the resin was cleaved with anhydrous HF, using standard conditions. The peptide was extracted from the resin with 90% acetic acid and purified by preparative HPLC.

Example IX

Synthesis of M570 Hydrochloride: F5c-OC2Y-Atmp.HCl

[0054] 4-Amino-2,2,6,6-tetramethylpiperidine (Aldrich) was coupled with Boc-(O-2,6-dichlorobenzyl)-tyrosine, using BOP in DMF solution. The Boc protecting group was removed by TFA and the product coupled with 2,3,4,5,6-pentafluorocinnamic acid in DMF, using BOP in the presence of excess DIEA at room temperature for 3 h. The DMF was removed in vacuo, the product was extracted into ethyl acetate and the solvent was evaporated. The residue was treated with 0.1-1.0 N HCl or 20% ethanolic HCl. The solvent was removed by evaporation in vacuo at room temperature. The residue was lyophilized from water-dioxane or crystallized from ethanol-ether.

Example X

Synthesis of M630: Dmac-OC2Y-Matp.TFA

[0055] 4-Methylamino-2,2,6,6-tetramethylpiperidine (Matp) was synthesized from 2,2,6,6-tetramethyl-4-piperidone (Aldrich) and methylamine by reductive amination with NaCNBH3. The Matp was coupled with Boc-(O-2,6-dichlorobenzyl)-tyrosine, using BOP in DMF solution. The Boc protecting group was removed by TFA and the product was coupled with 4-(dimethylamino)cinnamic acid in DMF, using BOP in the presence of excess DIEA at room temperature for 3 h. The DMF was removed in vacuo. The product was extracted into ethyl acetate and the solvent was evaporated in vacuo. The crude product was purified by HPLC, giving the TFA salt. The Dmac-OCTY-Matp.TFA salt can be converted to its HCL salt as in Example IX above.

Example XI

Synthesis of M638: DDD-(DArg-Igl-Arg-Matp)2

[0056] In sequence, Boc-Arg(Tos), Boc-Igl and Boc-DArg(Tos) were coupled to 4-methylamino-2,2,6,6-tetramethylpiperidine (Matp), using BOP as coupling agent in DMF in the presence of excess DIEA at room temperature for 3-5 h. After removal of DMF in vacuo, the product was extracted into ethyl acetate. After evaporation of the solvent, the residue was treated with TFA-DCM to remove the Boc group. TFA was removed in vacuo. The DArg(Tos)-Igl-Arg(Tos)-Matp.TFA was treated with dodecanedioyl dichloride (0.55 equiv) and DIEA (5 equiv) in DCM for 5 h. The protecting groups were cleaved by HF and the lyophilized product was purified by HPLC. The M638.TFA salt was converted to its HCl salt, using 0.1-1.0 N HCl or 20% ethanolic HCl as in Example IX above.

Example XII

Synthesis of M590: Atmp-Igl-Pac-α-Sbl-Lys-B9430

[0057] In sequence, Boc-Igl, Boc-Pac and mono-methyl sebacate were coupled to 4-amino-2,2,6,6-tetramethylpiperidine (Atmp), using BOP coupling agent in DMF in presence of excess DIEA at room temperature for 3-5 h. DMF was removed in vacuo and the product was extracted into ethyl acetate. After evaporation of the solvent, the methyl ester was hydrolyzed in methanol by 1N NaOH. The crude product (0.025 mmol Atmp-Igl-Pac-Sbl) was coupled to the peptide resin (0.02 mmol Lys(2-ClZ)-DArg(Tos)-Arg(Tos)-Pro-Hyp-Gly-Igl-Ser(Bzl)-DIgl-Oic-Arg(Tos)-Merrifield resin) using BOP/DIEA activation in DMF. The heterodimer peptide was cleaved from the resin with HF, using standard conditions. The peptide was extracted from the resin with acetic acid and purified by preparative HPLC.

Example XIII

Synthesis of M872: c[DArg-Arg-Eac-Ser-DF5F-Oic-Arg]

[0058] Following standard solid phase synthesis procedures, Boc-DArg(Tos) was coupled to Boc-Arg(Tos) Merrifield synthesis resin, followed in sequence by Boc-Arg(Tos), Boc-Oic, Boc-DF5F, Boc-Ser(Bzl), and Boc-Eac, using HATU as coupling agent. After deprotection with TFA-DCM, the resin was cleaved with anhydrous HF using standard conditions. The peptide was extracted from the resin with 0.1% TFA-H2O/dioxane and lyophilized. The peptide trifluoroacetate was cyclized with three equivalents of PyAOP and HOAt and 20 equivalents of DIEA in DMF at a concentration of 10−3 M. After removal of the solvent under reduced pressure, the product was lyophilized from dioxane-H2O and purified by HPLC.

Example XIV

Synthesis of M678: (Dns-DArg-Igl-Arg)2-DDA

[0059] In sequence, Boc-Arg(Tos), Boc-Igl and Boc-DArg(Tos) (2 equivalents) were coupled to 1,10-decanediamine using BOP as a coupling agent in DMF in presence of excess DIEA at room temperature for 3-5 h. DMF was removed in vacuo and the product was extracted into ethyl acetate. The solvent was evaporated in vacuo and the residue was treated with TFA/DCM to remove the Boc group. TFA was removed in vacuo, and the product was treated with dansyl chloride (2 equivalents) and an excess of DIEA in DCM for 5 h. The Tos groups were cleaved by HF and the crude product was purified by HPLC.

Example XV

Synthesis of M290: BTAC-(2-Nal-Atmp)3

[0060] The benzene-1,3,5-tris-carbamido-ε-caproic acid linker was made from 1,3,5-benzenetricarboxylic acid and N-Boc-ε-caproic acid methyl ester, using the BOP coupling method. The methyl ester was hydrolyzed in methanol by 1N NaOH. The product (1 equivalent BTAC) was coupled to 2-Nal-Atmp (3 equivalents) in DMF, using HATU as coupling agent. The solvent was removed in vacuo, and the residue was purified by HPLC. The BTAC-(2-Nal-Atmp)2-OH was also isolated as a by-product.

Example XVI

Synthesis of M1040: EDTA-(OC2Y-ATMP)4

[0061] Boc-(O-2,6-dichlorobenzyl)-tyrosine was coupled with 4-amino-2,2,6,6-tetramethylpiperidine overnight in DMF, using BOP as coupling agent in the presence of DIEA. After removal of DMF in vacuo, the residue was extracted into ethyl acetate and treated with TFA/DCM to cleave the Boc group. The TFA/DCM was evaporated in vacuo and the product (OCTY-ATMP) was lyophilized from dioxane/water. Ethylenediaminetetraacetic acid (0.25 equivalent EDTA) was coupled with OC2Y-ATMP trifluoroacetate (1 equivalent) in DMF, using BOP as coupling agent in the presence of DIEA. The solvent was removed in vacuo and the residue was purified by HPLC.

Example XVII

Assay of Anti-bradykinin Activity on Guinea Pig Ileum

[0062] Male Hartley guinea pigs that had been deprived of food overnight were sacrificed, and sections of terminal ileum, 25 mm in length, were dissected, attached to tissue holders and immersed in 10 ml tissue baths containing Krebs' solution bubbled with 95% O2/5% CO2. Tissues were placed under 1 g tension and incubated for 1 h equilibration. Concentration-effect curves were constructed to bradykinin in the absence and presence of new compounds. Bradykinin showed pD2=7.4, and antagonist B9430 showed pA2=7.9.

Example XVIII

Assay of Anti-bradykinin Activity on Cloned Human B2 Receptors

[0063] Chinese hamster ovary cells containing cloned and expressed human bradykinin B2 receptors were grown in cell cups of the Cytosensor microphysiometer in Ham's F-12 medium supplemented with sodium pyruvate and 10% FBS (Gibco 11765-054). For assay the cells were transferred to Ham's F-12 without bicarbonate or serum (Gibco 21700-075) and placed in the Cytosensor. Concentration-response curves were constructed to bradykinin in the presence or absence of new compounds. Bradykinin showed pD2=11, and antagonist B9430 showed pA2=10.5.

Example XIX

Colorimetric Tetrazolium Assay for Cell Survival

[0064] Cell growth and survival were measured by a rapid colorimetric assay based on the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Mosmann, J. Immunol. Methods 65: 55-63, 1983, with minor modifications). Briefly, 1,000 normal lung fibroblasts or normal epithelial BEAS-2B cells, 1,000 or 5,000 viable non-SCLC cells or 10,000 viable SCLC cells were plated in 100 μL of growth medium in 96-well flat-bottomed microtiter plates. Cells were incubated overnight to allow recovery. Compounds to be tested were added to the cells in triplicate in a range of concentrations and the cells were incubated at 37∞C., 5% CO2, with 100% humidity. Control cells were treated in the same way without antagonists. All wells had a final volume of 200 μL. Plates were incubated for 4 days, allowing sufficient time for cell replication and compound-induced cell death to occur. On day 5, 25 μL of a 2 mg/mL solution of MTT (Sigma) dissolved in RMPI-1640 was added to each well. The plate was incubated for 4 h at 37∞C. The supernate was removed and the blue formazan complex was dissolved by adding 100 μL of 0.02 N HCl in 75% isopropanol to all wells. Absorbance was immediately determined using a scanning multiwell plate reader. B9870 caused 50% cell death at a concentration of 0.15 μM under these conditions.

Example XX

Measurement of Apoptosis in Cultured Cells

[0065] Apoptosis, also known as programmed cell death, is the phenomenon by which a cell dies following a series of gene-mediated events, in response to a wide range of intracellular and extracellular agents. Apoptosis, a counterpart of mitosis, plays an important role in the development and homeostasis of many organisms and tissues. It serves to regulate cell numbers, to shape developing organisms and as a defense against potentially harmful agents. Apoptosis is not the only mode of cell death. Necrosis is a type of cell death which is nonspecific and frequently occurs when cells are exposed to high doses of toxic agents. Such exposure usually results in the loss of ionic homeostasis. Unlike apoptosis, necrosis does not seem to be genetically influenced.

[0066] Apoptotic and necrotic cells have different appearances which allow them to be distinguished microscopically. Necrotic cells and their mitochondria swell, the cell membrane eventually ruptures, and internal organelles become distended. As a result of the membrane rupture, inflammation occurs in the surrounding tissue. In contrast, the nuclei of apoptotic cells become fragmented into several smaller nuclear bodies, which are quickly recognized by phagocytes and engulfed, and no inflammatory response occurs. Therefore, it is useful to develop chemotherapeutics which induce apoptosis, rather than necrosis, in order to avoid inflammation and the toxic agents which are often released from necrotic tumor cells.

[0067] We have used differential fluorescent dye uptake and cellular morphology to distinguish viable and dead cells with apoptotic and/or necrotic morphologies. We have used Rhodamine 123 to stain active mitochondria in viable cells, Hoechst 33324 to stain DNA in both viable and dead cells, and Propidium Iodide to stain DNA in dead cells. These cell subpopulations may be distinguished by the different manners in which they take up the fluorescent probes. The dead apoptotic and necrotic subpopulation, which has lost its membrane potential and organelle function, takes up Propidium Iodide and Hoechst 33324. Since the cells in this subpopulation are dead, the mitochondria are not active and thus there is little or no uptake of Rhodamine 123. Under the fluorescence microscope with a DAPI filter, nuclei in these cells appear pinkish in color due to the mixing of both Propidium Iodide and Hoechst 33324 dyes. Necrotic cells have intact nuclei while apoptotic cells have fragmented multi-nucleated bodies. In contrast, the viable apoptotic subpopulation has an intact membrane but inactive mitochondria. As a result, the fragmented multi-nucleated bodies (a hallmark of apoptotic cells) in these cells take up only Hoechst 33324, which gives them a blue appearance under the fluorescence microscope, but are unable to take up Propidium Iodide or Rhodamine 123. The subpopulation of viable cells has both intact cell membranes and active mitochondria. These cells take up both Hoechst 3324 and Rhodamine 123. Microscopically these cells appear to have single normal blue nuclei when examined with a DAPI filter and bright green mitochondria when examined with a FITC filter.

Example XXI

Inhibition of Tumor Growth in vivo in Nude Mice

[0068] Representative peptide and non-peptide compounds having high in vitro cytotoxic activity were tested against implanted tumors in vivo. Athymic nude mice were implanted subcutaneously with either single cell suspensions (2 million SCLC cells or 1 million NSCLC cells) or with small fragments (3×3 mm) of tumors minced from previously grown nude mouse heterotransplants. On the seventh day after tumor implantation groups of 5 mice bearing implants were injected intraperitoneally daily with the compounds being tested at 1, 5, or 10 mg/kg/day; control animals were injected with an equal volume of isotonic saline. Tumor size was measured with a caliper three times per week. Tumor volume was calculated by the formula:

Volume (cc)=π×(length)×(width)2/6

[0069] Results of representative in vivo tests are given in FIGS. 1-8. For comparison, bradykinin antagonist peptide dimers B9870 and B10054 caused marked inhibition of growth of the SCLC line SHP-77 at a dose of 5 mg/kg/day.

Example XXI

Data

[0070] Examples of peptides and peptide mimics related to the C-terminal part of bradykinin antagonist peptides and their biological activities on cancer cells and bradykinin responses are given in Table 1.

[0071] Many compounds not directly related to the structure of bradykinin were synthesized and tested for anti-tumor and anti-bradykinin activity. These are listed in Table 2.

[0072] Cyclic peptides related to bradykinin and bradykinin mimics are reported in Table 3, along with their biological activity on cancer cells and anti-bradykinin activity.

[0073] Structures of previously described known peptides which have been found to be active against cancers in vivo are included in Table 4.

[0074] Cytotoxic activity in vitro of compounds M570 and M590 against various standard strains of prostate cancer is reported in Table 5.

[0075] Standard abbreviations were used for natural amino acids. For non-natural amino acids, derivatizing groups and other chemicals, the abbreviations listed in Table 6 are used.

6TABLE 1ACTIVITIES OF FEPTIDESRELATED TO BRADYKININ STRUCTURENUMBERSTRUCTUREMTTaGPIbHUMANcBKdArg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-ArgB9430dDArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg1208.2B9870-2dSUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-0.158.4Arg)B8838DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-Arg —7.0B8840DArg-Arg-Pro-Hyp-Gly-Phe-Ser-DCpG-CpG-Arg—6.8B8858DArg-Arg-Pro-Hyp-Gly-Thi-Ser-CpG-DCpG-DArg—5.2B8994DArg-Arg-Pro-MeP-Gly-CpG-Ser-DCpG-CpG-Arg——B9074Dhq-DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-—6.3ArgB9126Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-—6.4Oic-ArgB9126-2Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-—7.3Oic-ArgB9224-2Aca-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-(D,L)Igl-Oic-—8.4ArgB9882α-Sub-Lys(εFlu)-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-——Oic-Arg└DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg——B9914Oic-Arg—WkB9916DIgl-Oic-Aig—WkB9490Dcg-Digl-Oic-Arg>60WkB9918Ser-Digl-Oic-Arg——B9920Igl-Ser-DIgl-Oic-Arg——B9922Gly-Igl-Ser-DIgl-Oic-Arg—WkB9924Hyp-Gly-Igl-Ser-DigI-Oic-Arg——B9926Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg——B9950α-Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg8— |Sub-Arg-DNMF-DTrp-Phe-DTrp-LeuB9956α-DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-——Oic-Arg)2B9960DArg-Arg-Nig-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg—7.7B9966DArg-Arg-NMF-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg—6.9B10010DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Nc7G-Arg—7.7B10014DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nc6G-Arg—7.6B10054DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-0.37.1Arg)2B10062DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-NH2Inact7.1B10082SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-0.77.2NH2)2B10084BApG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg>208.1B10088DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-Eac-47.1Eac-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-ArgB10092(Gun)2-BApG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl->208.7Oic-ArgB10098(DArg-Arg-Pro-Hyp)2Dpr-Igl-Ser-DIgl-Oic-Arg205.3B10100-2TDIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-18.0Arg)2B10100-1Moti-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg47.8B10104-2TDIM-(DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-48.0Arg)2B10104-3Moti-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg208.1B10160Leu-DTrp-Phe-DTrp-DNMF-Eac2-DArg-Arg-Pro-106.3Hyp-Gly-Igl-Ser-DIgl-Oic-ArgB10162Leu-Leu-DTrp-Phe-DTrp-DNMF-Eac2-DArg-Arg-76.3Pro-Hyp-Gly-Igl-Ser-Digl-Oic-ArgB10198-1DDD-(Eac-Arg-Digl-Oic-Arg)2—5.7B10198-2DDD-(Eac-Arg-Digl-Oic-Arg)215—B10200DDD-(Eac-Eac-Arg-DIgl-Oic-Arg)2165.8B10238F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg1508.1B10252EGS-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)2258.3B10282Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-Arg—7.3B10284Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-NH2—7.7B10382DArg-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg——B10384DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg——B10386DDD-(DmK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-——Arg)2B10388DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg——B10390DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg——B10392DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg——B10394F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-PFF-Arg——B10396F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg——M2Dcg-D-2-Nal-Arg——M10Dcg-2Nal-Arg—4.8—M20Gun-2-Nal-Arg—4.6M42Gun-Eac-DIgl-Oic-Arg—5.0M68Dcg-BtA-Arg—4.9M70Dcg-Igl-Arg—4.8M78Dcg-Apa-Arg—5.6M84Dcg-Ile-Arg—5.1M86Dcg-Ac6c-Arg—5.0M88Gun-Ica-Arg—4.7M94Dcg-Aic-Arg—WkM96Dcg-(D,L)Ata-Arg—4.7M118-1Ac-PaF(Mcg)-Arg—4.9M118-3Ac-PdF-Arg—5.4M124Dcg-Gly-Cmp-Arg—4.7M128Dcg-Gly-Oic-Arg—WkM130Dcg-F5F-Arg204.8M132F5bz-F5F-Arg60WkM134Dcg-Trx-Arg—4.9M142Ac-PaF(Sin)-Arg—WkM146-1Ac-PaF(Mcg)-p-ABz-Arg—InactM146-2Ac-PaF(Dcg)-p-ABz-Arg—4.9M148F5c-p-ABz-Arg—5.1M160Ste-2-Nal-Arg—WkM176F5c-pABz-2Nal-ArgInact5.4—M196F5c-Gly-mABz-2Nal-ArgInact5.1—M198Ac-Pac-Gly-m-Abz-2-Nal-Arg—5.1M200-1Mcg-Pac-Gly-m-ABz-2-Nal-Arg—InactM200-2Dcg-Pac-Gly-m-ABz-2-Nal-Arg—4.9M216F5c-p-APa-Arg>180—M226DDD-(Arg-DIgl-Oic-Arg)2355.7InactM232-1Dcg-Atpc-Arg—4.7M232-3Dcg-2-Nal-Atpc-Arg—5.1M346Dcg-p-Amb-Arg—4.6M348F5c-p-Amb-Arg—4.7M352F5c-p-Amb-APa-Arg—4.7M370F5c-Arg—4.8M372F5c-APb-Arg—4.6M374Tfmc-Arg—4.6M380F5c-Tyr-Arg—InactM382F5c-Tic-Arg—4.7M388F5c-Lys{(CH3)3}-Arg—4.9M392F5c-Ana-Arg—4.5M394F5c-Bip-Arg—4.7M398F5c-Pac-Arg—InactM400DDD-(pABz-2Nal-Arg)2225.111.5M406Arg-Eac-DIgl-Ana-Arg—InactM410F5c-Phe-Arg—5.4M412F5c-m-APa-Arg—5.8M416F5c-3-Pal-Arg—WkM420F5c-hPhe-Arg607.010.9M424F5c-Thi-Arg—4.6M426F5c-Trp-Arg—InactM442F5c-Oic-Arg——M446F5c-2Nal-Arg604.79M450F5c-2Nal-Arg-NH2264.9InactM484DDD-(Pac-2Nal-Arg)225InactInactM494DDD-(Lys-Pac-Gly-mABz-2Nal-NH2)2335.1InactM498DDD-(Pac-2Nal-Arg-NH2)2244.9InactM500DDD-(pABz-2Nal-Arg-NH2)240011.4M504DDD-(Pac-2Nal-DArg-NH2)2115.4WkM508DDD-(DArg-2Nal-Arg)223Inact—M510DDD-(DArg-2Nal-Arg-NH2)28Inact11M512F5c-OC2Y-Arg705.711M516DDD-(DArg-Arg-Aud-Pac-2Nal-Arg)21.40AgM518DDD-(DArg-OC2Y-Arg)215Wk10M520F5c-OBS-ArgInact6.17M528F5c-MBC-ArgInactInactM540Pya-hPhe-Arg>100WkM542Dca-hPhe-Arg80WkM550F5c-OBT-Arg80InactAgM552DDD-(p-ABz-hPhe-Arg)2InactInactM554DDD-(DArg-hPhe-Arg)2—5.1M558Dcg-hPhe-Arg100WkM560DDD-(DArg-hPhe-Arg-NH2)250WkM564DDD-(DArg-OBS-Arg)2—WkM590Atmp-Igl-Pac-α-Sbl-Lys-B94304.57.5InactM598DDD-(Arg-DIgl-Oic-Arg-OMe)213—10M600α-DDD-(Lys-B9430-OMe)21.26.4AgM608DDD-(Eac-Arg-DIgl-Oic-Arg-OMe)213—InactM612F5c-DArg-hPhe-ArgInactWkM676DDD-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)2——M682F5c-Lys(F5bz)-Arg—4.9M686F5c-NMF-Arg295.6M688F5c-Dpr(Fbz)-Arg—InactM690F5c-Dpr(Paa)-Arg—4.8M692DDD-(DArg-Arg-Aud-Pac-hPhe-Arg)2—WkM696F5c-DArg-Eac-2Nal-ArgInact5.1—M698F5c-DArg-Arg-Aud-Pac-2Nal-Arg7.1Wk—M706Cin-hPhe-ArgInactWkM708Ppa-hPhe-ArgInact5.8M710DDD-(DArg-Arg-Aud-Pac-2Nal-DArg-NH2)21.7WkM714F5c-PCF-ArgInactWkM718F5c-PFF-Arg95.1M720F5c-PaF(Ppa)-ArgInact4.8M726D-Arg-Arg-Aud-PaF(F5c)-ArgInact5.6M728DDD-(DArg-Arg-Aud-PaF(F5c)-Arg)245.3M730F5c-DhPhe-Arg—4.7M732F5c-PNF-Arg—4.9M734DDD-(DArg-Arg-Aud-Pac-PaF(Fbz)-Arg)21.85.3M738F5c-DArg-Eac-hPhe-ArgInact5.3M746DDD-(Pac-hPhe-Arg)2InactInactM752-2Pac-hPhe-ArgInactWkM752-5Aaa-Ser-Pac-hPhe-ArgInactWkM752-6Aaa-Pac-hPhe-ArgInactWkM754Aaa-DPhe-hPhe-ArgInact4.6M756DDD-(DPhe-hPhe-Arg)2185.2M758Saa-hPhe-Arg—WkM764Aaa-DTic-hPhe-Arg—4.8M766F5c-DArg-Arg-Aud-DTic-hPhe-Arg—5.1M770DDD-(DArg-Arg-Aud-DTic-hPhe-Arg)2 8InactM772Aaa-DIgl-hPhe-Arg—4.9M774F5c-DArg-Arg-Aud-DIgl-hPhe-Arg8InactM776DDD-(DIgl-hPhe-Arg)2305M778-1Pcc-hPhe-Arg—WkM780Mca-hPhe-Arg—WkM782Cca-hPhe-Arg—WkM784Ac-OC2Y-ArgInactWkM786DDD-(DArg-Arg-Aud-DIgl-hPhe-Arg)23.2WkM788F5c-DArg-Arg-Aud-DTic-Oic-Arg95M790DDD-(DArg-Arg-Aud-DTic-Oic-Arg)21.7InactM792F5c-DArg-Arg-Eac-Ser-DTic-Oic-Arg>1004.9M794DDD-(DArg-Arg-Eac-Ser-DTic-Oic-Arg)221InactM796F5c-DArg-Arg-Eac-Ser-DF5F-Oic-Arg316.5M802F5c-Lys-Ser-DF5F-Oic-ArgInact6.3M804DDD-(DArg-Arg-Eac-Ser-DF5F-Oic-Arg)27.37.7M806Ava-Igl-Ser-DF5F-Oic-ArgInact5.6M808DDD-(Lys-Ser-DF5F-Oic-Arg)2306.9M810F5c-F5F-Arg404.6M812F5c-PFF-Arg-NH215WkM814Ppa-PFF-ArgInactWkM816Dpa-PFF-Arg524.6M818DDD-(DArg-PFF-Arg-NH2)260WkM820DDD-(DArg-PFF-Arg)243InactM822DDD-(DArg-F5F-Arg)225MixedM826F5c-MFF-Arg76InactM828F5c-3,4F2F-Arg—WkM838F5c-DArg-Arg-Aud-DIgl-PFF-Arg7.45.1M842DDD-(DArg-Arg-Aud-DIgl-PFF-Arg)21.4InactM844DArg-Arg-Aud-DIgl-PFF-Arg12WkM846DDD-(DArg-Arg-Aud-DF5F-Oic-Arg)227.1M852F5c-DArg-Arg-Eac-Ser-DIgl-Oic-ArgInact5.9M854DDD-(DArg-Arg-Eac-Ser-DIgl-Oic-Arg)27.35.9M856F5c-DArg-Arg-Aud-Ser-DIgl-Oic-Arg215.4M858DDD-(DArg-Arg-Aud-Ser-DIgl-Oic-Arg)246.3M860F5c-DArg-Arg-Add-Ser-DIgl-Oic-Arg65.4M862DDD-( DArg-Arg-Add-Ser-DIgl-Oic-Arg)21.35.6M864DDD-(DArg-Arg-Add-Ser-DIgl-PFF-Arg)21.8InactM868Ac-Darg-Arg-Aud-DF5F-Oic-Arg556.5M888F5c-DArg-Arg-Aud-Ser-D5F5-Oic-Arg12.56.6M890DDD-(DArg-Arg-Aud-Ser-DF5F-Oic-Arg)21.75.5M922DDD-(DNiK-Arg-Eac-Ser-DF5F-Oic-Arg)2 ——M926ζ-SUB-(ApC-F5F-Arg)2Inact—M930α-DDD-(ApC-F5F-Arg)2Inact—M932DDD-(DArg-Arg-Eac-Ser-DIgl-PFF-Arg)26.0—M936DDD-(DNiK-PzO-Eac-Ser-DF5F-Oic-Arg)2——M944DDD-(DArg-Arg-Eac-Ser-DF5F-PFF-Arg)26.7—M946F5c- DArg-Arg-Eac-Ser-D5F5-PFF-Arg——M950α-DDD-(K-DArg-Arg-Eac-Ser-DF5F-Oic-Arg)26.7—M952DDD-(DmK-DArg-Arg-Eac-Ser-D5F5-Oic-Arg)2——M954Aaa-DArg-Arg-Eac-Ser-D5F5-Oic-Arg10—M956Aaa-DArg-Arg-Aud-Ser-D5F5-Oic-Arg14—M958F5bz-DArg-Arg-Aud-Ser-D5F5-Oic-Arg18—M960Aca-DArg-Arg-Aud-Ser-D5F5-Oic-Arg21—M96433Dp-DArg-Arg-Aud-Ser-D5F5-Oic-Arg4-8—M968Dmac-DArg-Arg-Aud-Ser-D5F5-Oic-Arg15—M972F5pa-DArg-Arg-Aud-Ser-DF5F-Oic-Arg——M974DDD-(PzO-F5F-Arg)2——M976DDD-(DNiK-F5F-Arg)2——M978DDD-(DPzK-F5F-Arg)2——M980DDD-(DPzO-F5F-Arg)2——M1024SUB-(DArg-Arg-Eac-Ser-DF5f-Nc7G-Arg)2147.2M1026DTP-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)2706.9M1028SBEC-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)2286.7M1030EGS-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)2517.0M1034DDD-(DArg-F5F-DArg-NH2)2——M1036DDD-(DArg-F5F-DArg)2405.4M1038ε-SUB-(Lys-DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)2—6.4M1042Aca-DArg-Arg-Eac-Ser-DF5F-Oic-Arg——M1044Gun2-BApg-DArg-Arg-Eac-Ser-DF5F-Oic-Arg——M1046(F5c-DArg-Igl-Arg)2-DDA——Footnotes: aED50 for killing of SCLC strain SHP-77 in vitro, μM. bpA2 for bradykinin antagonist activity on isolated guinea pig ileum. The pD2 of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency. cpA2 for bradykinin antagonist potency on cloned human B2 receptors, pM. The pD2 for bradykinin is 11. Higher numbers indicate higher potency. dData included for comparison Inact = inactive; Mixed = showing both agonist and antagonist activity; Wk = weak

[0076]

7

TABLE 2

ACTIVITIES OF COMPOUNDS NOT RELATED TO BRADYKININ

NUMBER
STRUCTURE
MTTa
GPIb
HUMANc

B9948
Arg-DNMF-DTrp-Phe-DTrp-
2.8
Wk

Leu

B10222
DNMF-DTrp-Phe-DTrp-LeuΨ
6.0
5.2

(CH2NH)Leu-NH2

B10224-1
α-DDD-(Lys-DNMF-DTrp-Phe-
13
—

DTrp-

LeuΨ(CH2NH)Leu-NH2)2

B10224-2
α-DDD-(Lys-DNMF-DTrp-Phe-
7
—

DTrp-LeuΨ(CH2NH)Leu-NH2)2

B10228
DDD-(DNMF-DTrp-Phe-DTrp-
40
Wk

LeuΨ(CH2NH)Leu-NH2)2

B10242
Arg-Pro-Lys-Pro-DTrp-Gln-
40
5.6

DTrp-Phe-DTrp-

LeuΨ(CH2NH)Leu-NH2

B10244
DArg-Arg-Pro-Lys-Pro-DTrp-
12
5.4

Gln-DTrp-Phe-

DTrp-LeuΨ(CH2NH)Leu-NH2

B10246
DArg-Pro-Lys-Pro-DTrp-Gln-
12
6.1

DTrp-Phe-DTrp-

LeuΨ(CH2NH)Leu-NH2

>278
F5c-Iqa-Atmp
9
5.3
—

M8
Gun-Eac-D2Nal-PgF
—
Inact

M12
Dcg-Igl-Aqu
20
5.0
—

M18
Dcg-2Nal-Aqu
30
6.6
—

M26
Gun-2Nal-GaP
—
4.9

M30
Dcg-2Nal-Apa
—
5.4

M32
Gun-2Nal-Apa
—
4.8

M36
Dcg-D2Nal-Apa
—
5.0

M38
Gun-D2Nal-Apa
—
4.9

M62
Dcg-2Nal-Ama
—
4.8

M64
Dcg-2Nal-APa-Sud
—
Ag

M72-1
Dcg-Igl-Apa
—
4.7

M72-2
Dcg-Igl-APa(anisyl)
—
4.6

M76
Dcg-2Nal-mABz
—
4.9

M92-1
Dcg-2Nal-mA2Bz
—
5.0

M92-2
Dcg-2Nal-mA2Bz(Gun)
—
4.8

M92-4
Dcg-2Nal-mA2Bz(Dcg)
—
5.0

M104
Dcg-2Nal-3Pal
—
4.9

M112
Dcg-D2Nal-mABz
—
5.1

M120
Dcg-2Nal-pABz
—
4.7

M122-1
Mcg-APa-mABz
—
5.0

M122-2
Dcg-Apa-mABz
—
4.6

M136
Sin-F5F-3Pal
—
Inact

M162
Dcg-2Nal-Asp
—
4.9

M168-1
2Nap-PaF(Mcg)
—
4.8

M168-2
2Nap-PaF(Dcg)
—
4.7

M172
Inp-Dpr(Dcg-2Nal)
—
4.9

M174
Dcg-Asp-Aqu
—
Inact

M180
F5c-pABz-2Nal
—
5.1

M188B
Dcg-2Nal-Asp(Aqu)
—
5.5

M202
F5c-Gly-mABz-2Nal
—
5.1

M204
Ac-Pac-Gly-mABz-Nal
—
5.0

M218
2Nal-Atmp
Inact
4.8

M222
Dcg-2Nal-Atmp
15
6.8
Inact

M228-2
Dcg(Me)-2Nal-Atmp(Me)
15
7.6
—

M236
Dcg-Igl-Atmp
>50
4.7
—

M240
Dcg-F5f-Atmp
32
5.1
—

M244A
Dcg-2Nal-Atpm
12
5.0

M244B
Dcg-2Nal-Atpc
Inact
4.9

M246
Dcg-D2Nal-Atmp
>50
5.7

M248
F5c-2Nal-Atmp
3.2
6.2
—

M250
Aca-2Nal-Atmp
—
5.2

M252
Dhq-2Nal-Atmp
Inact
4.8

M254
TDIM-(2Nal-Atmp)2
5
5.1
—

M254-1
TDIM-(2Nal-Atmp)2
5
5.1

M254-2
TDIM-(2Nal-Atmp)2
5
5.8

M258
Dcg-Igl-Aptp
—
5.0

M262
Dcg-D2Nal-Atmp
6
5.3

M264
Dcg-Trp-Atmp
16
4.7
—

M266
Dcg-Apa-Atmp
42
4.8
—

M268
F5c-2Nal-Tpac
10
5.2
—

M270
Dcg-2Nal-Tpac
—
6.1

M272
Dpa-2Nal-Atmp
9
5.2
—

M274
Sin-2Nal-Atmp
36
4.7
—

M276
Dca-2Nal-Atmp
4.6
5.3
—

M280
TDIM-(Igl-Atmp)2
6
5.2
—

M280-1
Ctim-Igl-Atmp
21
Wk

M280-2
TDIM-(Igl-Atmp)2
6
5.2

M286
Dtp-(2Nal-Atmp)2
24
5.1
—

M288
Boc-2Nal-Atmp
Inact
5.2
—

M288A
Boc-2Nal-Atmp
>85
5.2

M290-1
Btac-(2Nal-Atmp)2
>60
Wk

M290-2
Btac-(2Nal-Atmp)3
20
Wk

M292
Pac-Igl-Atmp
40
Wk

M294
DDD-(Pac-Igl-Atmp)2
1.8
Inact
10.3

M296
Pya-Bip-Atmp
15
Wk

M302
Atcp-2Nal-Atmp
3.5
5.2

M304
TDIM-(2Nal-Dmm)2
4.2
5.9
—

M306
Gbz-2Nal-Atmp
>100
—

M308
Pac-2Nal-Atmp
>75
5.0

M310
DDD-(Pac-2Nal-Atmp)2
1.2
5.1
Inact

M312
Tfmc-2Nal-Atmp
3.2
5.5
—

M314
F5c-2Nal-Aqd
25
4.6

M316
F5c-Tyr-Atmp
50
—

M318
F5c-Tyr(Bzl)-Atmp
3.6
5.1
—

M320
F5c-Oic-Atmp
13
—
—

M322
F5c-Tic-Atmp
7.6
—
—

M324
Dmac-2Nal-Atmp
3
5.2
—

M336-1
Dcg-2Nal-Asp-(R,S)Aqu
—
5.1

M336-2
Dcg-2Nal-Asp-(R,S)Aqu
—
5.4

M340
Dcg-Pac-Gly-mABz-2Nal
—
4.8

M342
Dcg-2Nal-Asp-Atmp
—
5.4

M350
Dcg-2Nal-Glu-Atmp
—
5.0

M354
Dcg-2Nal-PgF
—
5.2

M362
Dcg-pAPa-Asp-Atmp
—
4.9

M364
F5c-pAPa-Asp-Atmp
—
4.7

M368
Tfmc-pAPa-Asp-Atmp
—
4.7

M396
F5c-2Nal-Cys(SO3H)-Atmp
—
5.0

M408
Pya-2Nal-Cyh
22
4.6
11.5

M418
F5c-BtA-Atmp
3.8
7.0
10.3

M422
Pya-pABz-2Nal
52
—
Inact

M428
Pya-Gly-mABz-Aqd
>300
—

M430
DDD-(BtA-Atmp)2
18
5.3
11.3

M432
DDD-(2Nal-Asp-Atmp)2
70
—
10

M436-1
TDIM-BtA-Atmp
8
4.8

M436-2
TDIM-(BtA-Atmp)2
4.5
5.8
Ag

M438
F5c-3Pal-Atmp
26
4.8
10

M440
Dcg-BtA-Atmp
30
—

M448
Dmac-BtA-Atmp
2.7
5.7
Ag

M456
F5c-Cys(Meb)-Atmp
4.7
5.3
Inact

M460
DDD-(3Pal-Nal-Cyh)2
15
Wk

M466
F5c-2Nal-3Ampy
Inact
Wk

M470
F5c-2Nal-Ampz
11
5.2
Inact

M472
Dmac-2Nal-Ampz
25
5.3
Inact

M474
Pya-2Nal-3Abza
35
Wk
Inact

M476
Tha-BtA-Atmp
15
4.6
Inact

M478
Dmac-2Nal-Thm
30
5.1
Inact

M480-1
HOOC-DDD-Pac-2NaL-Ampz
45
5.1

M480-2
DDD-(Pac-2Nal-Ampz)2
—
5.6

M492
F5c-mABz-2Nal-Ampz
45
5.1
Inact

M506
Mse-Pac-BtA-Atmp
11
4.9
—

M526
F5c-2Nal-Dmp
10
5.4
Inact

M536
F5c-2Nal-Dmab
4
Wk
Inact

M538
DDD-(Pac-2-Nal-Dmp)2
>80
Wk

M568
F5po-2Nal-Atmp
10
5.8
Ag

M570
F5c-OC2Y-Atmp
1.8
5.6
Ag

M572
Dca-2Nal-Acep
2.6
Wk
Wk

M574
Dns-Tyr(Bzl)Atmp
4.5
—
Inact

M582
Dmac-OC2Y-Atmp
3
5.4
9.5

M584-A
DDD-[DArg(Tos)-2Nal-Atmp]2
5
Inact
10.3

M584-B
DDD-(DArg-2Nal-Atmp)2
5
5.7
11.3

M586-A
Mse-Pac-Igl-Atmp
15
5.3
12

M586-B
Seb-Pac-Igl-Atmp
40
Wk
12.3

M588
α-DDD-(Lys-DArg-2Nal-
9.4
Wk
10

Atmp)2

M592
F5c-OC2Y-Matp
1.5
4.9
Ag

M594
F5c-MC2Y-Atmp
3.7
5.0
8

M594
F5c-MC2Y-Atmp
3.7
5.0
8

M596-A
DDD-[Arg(Tos)-2Nal-Atmp]2
15
5.0

M596-B
DDD-(Arg-2Nal-Atmp)2
8.2
Wk
Inact

M602
Chc-OC2Y-Atmp
12
—
10.8

M604
Pac-2Nal-Ecap
43
4.5

M606
DDD-(Pac-2Nal-Api)2
30
5.0
10

M614
F5c-(N-Dmb)-Tyr(Bzl)-OMe
9.1
Wk

M616
DDD-(Pac-1Nal-Atmp)2
1.4
5.4
—

M618
F5c-DArg-2Nal-Arg-Matp
18
—
—

M620
DDD-(DArg-2Nal-Arg-Matp)2
2.0
5.5
—

M622
F5c-OC2Y-Mapp
1.2
5.7
—

M624
Dns-OC2Y-Matp
1.4
5.1
—

M626
Pya-OC2Y-Matp
3.7
4.8
—

M628
Cin-OC2Y-Matp
1.6
5.2
—

M630
Dmac-OC2Y-Matp
1.6
5.0
—

M632
Atcp-OC2Y-Matp
1.4
5.4
—

M636
DDD-(DArg-Arg-Aud-Pac-
1.7
5.8
—

2Nal-Atmp)2

M638
DDD-(DArg-Igl-Arg-Matp)2
0.6
Inact

M640
DDD-(DArg-BtA-Arg-Matp)2
3.0
5.9

M648
F5c-PaF(Mes)-Atmp
Inact
5.0

M650
Atcp-OC2Y-Mapp
3.7
—
—

M652
Ppa-OC2Y-Mapp
7.5
5.7
—

M654
Sul-Atmp
Inact
4.5

M656
Sul-2Nal-Atmp
13
5.4

M660
DDD-(His-1Nal-Atmp)2
30
Wk
—

M662
F5c-tLeu-Atmp
Inact
5.2
—

M664
F5c-OCIY-Matp
1.2
5.0

M666
Dns-OCIY-Matp
1.3
5.0

M668
SBEC-(DArg-2Nal-Arg-Matp)2
3.4
5.2

M670
DTP-(DArg-Igl-Arg-Matp)2
Inact
5.1

M672
HDD-(DArg-Igl-Arg-Matp)2
—
—

M674
DDD-(DArg-F5F-Arg-Matp)2
3.5
Wk

M678
(Dns-DArg-Igl-Arg)2-DDA-
1.1
5.3

M724
F5c-DArg-Aud-OC2Y-
12
5.4

Gly-Atmp

M744
DDD-(DArg-2Nal-Arg-Dmab)2
3.4
5.3

M798
F5c-OC2Y-Dmab
37
—

M800
DDD-(DArg-OC2Y-Dmab)2
27
5.3

M832
F5c-PFF-Dmab
47
4.6

M834
DDD-(DArg-PFF-Arg-Dpea)2
1.6
5.3

M848
DDD-(DArg-F5F-Arg-Dmab)2
—
—

M880
DDD-(DArg-F5F-Arg-Dpea)2
—
—

M886-1
DDD-DArg-PFF-Arg-NH2
3.2
Wk

└DArg-PFF-Arg-Dpma

M886-2
DDD-(DArg-PFF-Arg-Dpma)2
—
Inact

M892
DDD-(DArg-PFF-Arg-PFF-
8.5
Wk

NH2)2

M900
DDD-(DArg-F5F-Arg-PaF-
6.3
—

NH2)2

M916
F5c-DArg-PFF-Arg-PFF-
5.7
4.9

NH2

M1032
DDD-(DArg-Igl-Mapp)2
15
5.4

M1040
EDTA-(OC2Y-Atmp)4
0.73
—

Footnotes:

a
ED50 for killing of SCLC strain SHP-77 in vitro, μM.

b
pA2 for bradykinin antagonist activity on isolated guinea pig ileum. The pD2 of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency.

c
pA2 for bradykinin antagonist potency on cloned human B2 receptors, pM. The pD2 for bradykinin is 11. Higher numbers indicate higher potency.

Ag = agonist; Inact = inactive; Wk = weak

[0077]

8

TABLE 3

ACTIVITIES OF CYCLIC PEPTIDES

NUMBER
STRUCTURE
MTTa
GPIb

B9458-2

—
6.1

B9462

7.3
6.0

B10302
c[DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg]
Inact
5.2

B10304
Aca-c[DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Nig-Oic-Arg]
Inact
6.4

B10306
c[Arg-DNMF-DTrp-Phe-DTrp-Leu]
Inact
Wk

B10312
α-DDD-(c[Lys-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DF5F-
3.8
—

Oic-Arg])2

M680
c[DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg]
—
—

M824
c[Ava-Igl-Ser-DF5F-Oic-Arg]
Inact
5.2

M850
c[DArg-Arg-Aud-DIgl-PFF-Arg]
1.4
5.1

M868-2
c[DArg-Arg-Aud-DF5F-Oic-Arg]
9.2
6.1

M870
c[DArg-Arg-Add-DF5F-Oic-Arg]
5.5
5.3

M872
c[DArg-Arg-Eac-Ser-DF5F-Oic-Arg]
2.2
Inact

M874
c[DArg-Arg-Add-Ser-DF5F-Oic-Arg]
11
5.0

M876
c[DArg-Arg-Aud-Ser-DF5F-Oic-Arg]
22.5
5.4

M878
c[DArg-Arg Add-DIgl-PFF-Arg]
7
Wk

M882
c[DArg-Arg-Add-Ser-DIgl-PFF-Arg]
4.5
Inact

M896
c[DArg-Arg-Eac-DIgl-PFF-Arg]
65
Wk

M902
c[DArg-Arg-Ava-Ser-DIgl-PFF-Arg]
30
5.5

M906
c[DArg-Arg-Eac-DF5F-Oic-Arg]
45
Wk

M908
c[DArg-Arg-Ava-Ser-DF5F-Oic-Arg]
40
4.9

M910
c[Bala-DArg-Arg-Eac-Ser-DF5F-Oic-Arg]
42
5.2

M924
c[Suc-DArg-Arg-Eac-Ser-DIgl-PaF]-Arg
37
Wk

M934
c[DNiK-Arg-Eac-Ser-DF5F-Oic-Arg]
—
—

M940
c[DNiK-PzO-Eac-Ser-DF5F-Oic-Arg]
—
—

M986
c[Add-DArg-F5F-Arg]
—
—

Footnotes:

a
ED50 for killing of SCLC strain SHP-77 in vitro, μM.

b
pA2 for bradykinin antagonist activity on isolated guinea pig ileum. The pD2 of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency.

Inact = inactive; Wk = weak

[0078]

9

TABLE 4

PREVIOUSLY DESCRIBED

KNOWN PEPTIDES THAT NEWLY

SHOW IN VIVO ANTI-CANCER ACTIVITY

NUMBER
STRUCTURE

B9430
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg

B9330
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg

B10044
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg

B10050
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG

B10206
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg

B10288
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg

[0079] These compounds showed anti-tumor activity in vivo when tested by the procedure of Example XXI.

10TABLE 5CYTOTOXICITY INVITRO AGAINST STRAINS OF PROSTATE CANCERCOMPOUNDPROSTATE CANCER CELL LINESCLCNUMBERDU14TSULNCaPC-3PPC1SHP-77B98700.086.53.73.24.30.15M5701.22.83.01.63.01.8M5900.017.07.06.3124.5Numbers are ED50 (μM) for cytotoxic activity. Activity against SCLC strain SHP-77 is included for comparison.

[0080]

11

TABLE 6

ABBREVIATIONS USED FOR COMPOUNDS

B9430 =
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg

B9870 =
SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-

Oic-Arg)2

Aaa =
1-Adamantaneacetyl

AAA =
amino acid analysis

ABz =
Aminobenzoic acid

ABza =
Aminobenzyl alcohol

Ac =
Acetyl

Ac3c =
1-Amino-1-cyclopropanecarboxylic acid

Ac5c =
l-Amino-1-cyclopentanecarboxylic acid (“cyclo-Leu”)

Ac6c =
1-Aminocyclohexanecarboxylic acid

Aca =
1-Adamantanecarboxyl

Acep =
4-Amino-1-carbethoxymethyl-2,2,6,6-

tetramethylpiperdine

ADA =
1,3-Adamantanediacetyl

Add =
12-Aminododecanoic acid

Aib =
α-Aminoisobutyric acid

Aic =
2-Aminoindane-2-carboxylic acid

AlG =
α-Allylglycine (2-amino-4-pentenoic acid)

Ama =
Aminomethylanthranilic acid

Amb =
Aminomethylbenzoic acid

Ampy =
3-Aminomethylpyridine

Ampz =
1-Amino-4-methylpiperazine

Ana =
Anthranilic acid

APa =
p-Aminophenylacetic acid

APb =
p-Aminophenylbutyric acid

ApC =
S-3-Aminopropylcysteine

Api =
4-Aminopiperidine

Apmp =
4-Amino-1,2,2,6,6-pentamethylpiperidine

Aptp =
4-Amino-1-phenylmethyl-2,2,6,6-tetramethylpiperidine

Aqd =
4-Aminoquinaldine

Aqu =
3-Aminoquinuclidine

Arg(NO2) =
Arginine(Nitro)

Atc =
2-Aminotetralin-2-carboxylic acid

Atcp =
4-Amino-3,5,6-trichloropicolinic acid

Atmp =
4-Amino-2,2,6,6-tetramethylpiperidine

AtmpO =
4-Amino-2,2,6,6-tetramethylpiperidinyloxy

Atpc =
4-Amino-2,2,6,6-tetramethyl-4-

piperidinecarboxylic acid

Atpm =
4-Amino-4-methoxycarbonyl-2,2,6,6-

Tetramethylpiperidine (4-Amino-2,2,6,6-

tetramethyl-4-piperidinecarboxylic acid methyl

ester)

Aud =
11-Aminoundecanoic acid

Ava =
5-Aminovaleric acid

Azt =
Azetidine-2-carboxylic acid

BAla =
β-Alanine

BApG =
N,N-bis(3-aminopropyl)-glycine

BAPTA =
1,2-bis(2-Aminophenoxy)ethane-N,N,N′,N′,-tetraacetyl

Bip =
Biphenylalanine

Boc =
(tert-Butoxycarbonyl); [(1,1-dimethylethoxy)carbonyl]

BOP =
Benzotriazoyloxytris(dimethylamino)phosphonium

hexafluorophosphate

BPHD =
N,N′-bis(2,2,6,6-tetramethyl-4-piperidinyl)-

1,6-hexanediamine

BSH =
1,6-Bissuccinimidohexane

BtA =
3-Benzothienylalanine

BTAC =
Benzene-1,3,5-tris-carboxamido-6-caproyl

BTC =
1,3,5-Benzenetricarboxyl

Bz =
Benzoyl

Bzl =
Benzyl

CAcH =
cis-2-Amino-1-cyclohexanecarboxylic acid

Cca:
2-Chlorocinnamic acid

CDF =
p-Chloro-D-phenylalanine

ChA =
α-Cyclohexylalanine

Chc =
α-Cyano-4-hydroxycinnamoyl

ChG =
α-Cyclohexylglycine

CHO =
Chinese hamster ovary

CHTC =
1,3,5-Cyclohexanetricarboxyl

CHyp =
cis-4-Hydroxy-proline

Cin =
Cinnamoyl

CMeb =
S-(4-Methylbenzyl cysteine

CmF =
(Z) p-Chloro-2,3-methanophenylalanine

Cmp =
4-Carboxymethylpiperazine

CpA =
α-Cyclopropylalanine

CpG =
α-Cyclopentylglycine

CpGPΨ =
CpG pseudo(CH2NH) Arg

(CH2N)Arg

CPTA =
trans-1,2-Diaminocyclohexane- N,N,N′,N′-tetraacetyl

CTAC =
Cyclohexane-1,3,5-tris-carbamido-ε-caproyl

Ctim =
13-Carboxytridecanimidyl

Cyh =
Cyclohexylamine

Dabz =
Diaminobenzoic acid

DArg(NO2) =
Nitro-Arginine

Dca =
Dicyclohexylacetyl

Dcg =
N,N′-Dicyclohexylguanidyl

DCM =
Dichloromethane

DDA =
1,10-Decanediamine

DDD =
Dodecanedioyl

DDS =
2-Dodecen-1-ylsuccinyl

DEA =
N,N′-Diethylethylenediamine

DhP =
3,4-Dehydroproline

Dhq =
2,3-Dehydroquinuclidine-3-carboxyl

DIC =
Decahydroisoquinoline-3-carboxylic acid

DIEA =
Diisopropylethylamine

Dmab =
4-Dimethylaminobenzylamine

Dmac =
4-Dimethylaminocinnamyoyl

Dmb =
4-(Dimethylamino)benzyl

DmF =
2,4-Dimethylphenylalanine

DMF =
Dimethyl formamide

DmK =
ε-Dimethyllysine

Dmm =
2,6-Dimethylmorpholine

Dmp =
3-Dimethylaminopropylamine

DmtP =
5,5-Dimethyl-4-thiaproline

Dns =
Dansyl (5-dimethylamino-1-naphthalenesulfonyl)

22Dp =
2,2-Diphenylpropionyl

33Dp =
3,3-Diphenylpropionyl

Dpa =
Diphenylacetyl

Dpea =
Diphenylethylamine

Dpma =
Diphenylmethylamine

Dpr =
2,3-Diaminopropionic acid

DTP =
Dithiobis-propionyl

DTPA =
Diethylenetriaminepentaacetyl

Eac =
ε-Aminocaproic acid

Ecap =
N-Ethoxycarbonyl-4-amino-piperidine

(Ethyl 4-amino-1-piperidinecarboxylate)

EDA =
4,4′-Ethylenedianiline

EDP =
4,4′-Ethylenedipiperidine

EDTA =
Ethylenediaminetetraacetyl

EDTP =
Ethylenediaminetetrapropionic acid

EGS =
Ethylene glycol-bis-succinyl

EGTA =
Ethylene glycol-bis(β-aminoethyl ether)-

N,N,N′,N′-tetraacetyl

EOPC =
1,1′-Ethylenebis(5-oxo-3-pyrrolidinecarboxyl)

ETTA =
2,2′2″,2′″-[Ethanediylidenetetrakis(thio)tetrakisacetyl

F2F =
Difluorophenylalanine

F5bz =
Pentafluorobenzoyl

F5c =
2,3,4,5,6-Pentafluorocinnamoyl

F5F =
Pentafluorophenylalanine

F5pa =
2,3,4,5,6-Pentafluorophenylacetyl

F5po =
2,3,4,5,6-Pentafluorophenoxyacetyl

Fbz =
para-Fluorobenzoyl

Flu =
Fluorescein thiourea

Gaa =
Guanidinoacetyl

GaP =
2-Guanidyl-3-(4-aminophenyl)propionic acid

Gbz =
4-Guanidinobenzoyl

Glt =
Glutaryl

Gun =
Guanidyl

HATU =
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

HbQ =
4-Hydroxybutylglutamine

HDA =
1,6-Hexanediamine

HDD =
Hexadecanedioyl

HF =
Hydrogen fluoride

HFG =
Hexafluoroglutaroyl

HiG =
Hexahydro-2-indanylglycine

HOAt =
1-Hydroxy-7-azabenzotriazole

hPhe =
Homo-phenylalanine

HPLC =
high performance liquid chromatography

Hxa =
Hexanoic acid

Hyp =
trans-4-Hydroxyproline

Ica =
Indoline-2-carboxylic acid

Igl =
α-2-Indanylglycine

Ing =
α-1-Indanylglycine

Inp =
Isonipecotic acid

Iq2a =
6,7-Dimethoxy-3,4-dihydro-1-isoquinolineacetic Acid

Iq4a =
6,7-Dimethoxy-1,2,3,4-tetrahydro-1-

isoquinolineacetic acid

Lau =
Lauroyl

Leu(r)Leu =
Leu-pseudo(CH2NH)Leu

LeuΨ(CH2NH) =
Leu-pseudo(CH2NH)Leu

Leu

LDMS =
laser desorption mass spectrometry

mA2Bz =
3,5-Diaminobenzoic acid

MaG =
α-Methallylglycine (2-amino-3-methyl-

4-pentenoic acid)

Mapp =
4-(Methylamino)-1,2,2,6,6-pentamethylpiperidine

Matp =
4-(Methylamino)-2,2,6,6-tetramethylpiperidine

MatpO =
4-(N-methylamino)-2,2,6,6-tetramethylpiperidinyloxy

MBC =
S-(4-methylbenzylcysteine

MBHA =
Methylbenzhydrylamine

MC2Y =
N-Methyl-O-2,6-dichlorobenzyl-tyrosine

Mca =
2-Methylcinnamic acid

Mcg =
Monocyclohexylguanidyl

Meb =
Methylbenzyl

MeP =
2,4-Methanoproline

Mes =
Methanesulfonyl

MFE =
(E)-2,3-Methanophenylalanine

MFF =
meta-Fluorophenylalanine

Mosi =
Methoxy-suberimido

Moti =
14-Methoxytetradecanediimidoyl

Mse =
Methoxysebacyl

MTT =
(3-(4,5)-Dimethyltriazol-2-yl)-2,5-diphenyl

tetrazolium bromide

Nal =
β-Naphthylalanine

Nap =
Naphthoyl

Nba =
Norbornane-2-acetyl

Nbc =
Norbornenedicarboxyl

Nbi =
Norbornenedicarboximide

Nbn =
2-Aminonorbornane-2-carboxylic acid

Nc5G =
N-Cyclopentylglycine

Nc6G =
N-Cyclohexylglycine

Nc7G =
N-Cycloheptylglycine

Nc8G =
N-Cyclooctylglycine

Nig =
N-2-Indanylglycine

NiK =
ε-Nicotinoyllysine

NMF =
N-Methylphenylalanine

NSCLC =
non-small cell carcinoma

OBS =
O-Benzylserine

OBT =
O-Benzylthreonine

OBY =
O-Benzyltyrosine

OC2Y =
O-2,6-Dichlorobenzyltyrosine

OCIY =
O-2,6-Dichlorobenzyl-3,5-diiodotyrosine

Oct =
Octanoyl

Oic =
Octahydroindole-2-carboxylic acid

OMe =
O-Methyl

OMY =
O-Methyltyrosine

OSY =
Tyrosine O-sulfate ester

Paa =
Phenylacetyl

Pac =
4-Aminocinnamic acid

PaF =
p-Aminophenylalanine

Pal =
β-Pyridylalanine

Pba =
Phenylbutyryl

Pcc =
trans-2-Phenyl-1-cyclopropanecarboxylic acid

PCF =
p-Chlorophenylalanine

Pcpa =
α-Phenylcyclopentaneacetyl

PdF =
p-Dicyclohexylguanidylphenylalanine

PFF =
p-Fluorophenylalanine

PFS =
Perfluorosuberoyl

PgF =
p-Guanidinophenylalanine

PheOL =
Phenylalaninol

PhG =
Phenylglycine

Pip =
Pipecolic acid (“homo-Pro”)

PipA =
β-3-Piperidylalanine

PNF =
p-Nitrophenylalanine

Ppa =
Phenylpropionyl

Pya =
trans-3-(3-Pyridyl)acryloyl

PyAoP =
7-Azabenzotriazol-1-yloxytris(pyrrolidino)

phosphonium hexafluorophosphate

PzK =
ε-Pyrazinoyllysine

PzO =
4-Pyrazinoylornithine

Saa =
trans-Styrylacetic acid

SBEC =
Sulfo-bis-ethoxycarbonyl

Sbl =
Sebacoyl

SCLC =
small cell lung carcinoma

Seb =
Sebacyl

Sin =
Sinapinyl (3,5-dimethoxy-4-hydroxycinnamoyl-)

Ste =
Stearoyl

Sua =
Sulfanilamide (4-Aminobenzenesulfonamide)

SUB =
Suberyl

Suc =
Succinyl

Sud =
Sulfadiazine

SUIM =
Suberimidyl

Sul =
Sulindac

Tha =
t-Butyl-acetyl

TDIM =
Tetradecanediimidyl

TEA =
Triethylamine

TFA =
Trifluoroacetic acid

Tfmc =
trans-4-(Trifluoromethyl)cinnamoyl

Tha =
3-(2-Thienyl)acryloyl

Thi =
β-2-Thienylalanine

Thm =
Thiomorpholine

Thz =
Thiazolidine-4-carboxylic acid (4-thiaproline)

Tic =
1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid

TLC =
thin layer chromatography

TLeu =
tert-Leucine

TMF =
2,4,6-Trimethylphenylalanine

Tos =
p-Toluenesulfonyl

Tpac =
2,2,5,5-Tetramethyl-3-(aminoethyl)-pyrroline-

3-carboxamide

TREN =
tris(2-Aminoethyl)amine

Trx =
Tranexamic acid (trans-4-((Aminomethyl))

cyclohexanecarboxylic acid)

[0081]

	Number	Date	Country
	60097210	Aug 1998	US
	60141169	Jun 1999	US

	Number	Date	Country
Parent	09378019	Aug 1999	US
Child	10035662	Dec 2001	US

Anti-cancer compounds and methods related thereto

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Parent Case Info

Provisional Applications (2)

Continuations (1)